Moneycontrol
you are here: HomeNewsBusiness
Last Updated : Nov 13, 2018 01:08 PM IST | Source: PTI

Lupin gets USFDA nod for Asthma drug

The product approved by the United States Food and Drug Administration (USFDA) is a generic version of AstraZeneca Pharmaceuticals LP's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL, Lupin said in a regulatory filing.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug major Lupin on Tuesday said it has received approval from the US health regulator to market Budesonide Inhalation Suspension single-dose ampules, used for treating Asthma.

The product approved by the United States Food and Drug Administration (USFDA) is a generic version of AstraZeneca Pharmaceuticals LP's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL, Lupin said in a regulatory filing.

Quoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around USD 474.5 million in the US.

Shares of Lupin were Tuesday trading 1.30 per cent down at Rs 849.30 apiece on the BSE.
First Published on Nov 13, 2018 01:05 pm
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant